Your browser is no longer supported. Please, upgrade your browser.
Settings
ARTL [NASD]
Artelo Biosciences, Inc.
Index- P/E- EPS (ttm)-0.57 Insider Own5.07% Shs Outstand23.11M Perf Week-11.76%
Market Cap16.00M Forward P/E- EPS next Y-0.35 Insider Trans0.00% Shs Float21.55M Perf Month-11.96%
Income-6.60M PEG- EPS next Q-0.08 Inst Own16.30% Short Float5.90% Perf Quarter-30.84%
Sales- P/S- EPS this Y-25.60% Inst Trans-15.94% Short Ratio0.16 Perf Half Y-48.36%
Book/sh0.52 P/B1.21 EPS next Y9.30% ROA-66.30% Target Price4.67 Perf Year2.56%
Cash/sh- P/C- EPS next 5Y- ROE-69.80% 52W Range0.55 - 3.67 Perf YTD-13.70%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-82.72% Beta3.10
Dividend %- Quick Ratio24.30 Sales past 5Y- Gross Margin- 52W Low15.27% ATR0.10
Employees4 Current Ratio24.30 Sales Q/Q- Oper. Margin- RSI (14)32.71 Volatility11.30% 13.71%
OptionableNo Debt/Eq0.00 EPS Q/Q64.50% Profit Margin- Rel Volume0.18 Prev Close0.63
ShortableYes LT Debt/Eq0.00 EarningsNov 29 BMO Payout- Avg Volume7.84M Price0.63
Recom1.50 SMA20-26.94% SMA50-21.54% SMA200-45.88% Volume871,606 Change0.63%
Feb-12-21Initiated Ladenburg Thalmann Buy $7
Nov-29-21 08:30AM  
Nov-11-21 08:30AM  
Nov-02-21 07:33AM  
Sep-08-21 08:30AM  
Aug-11-21 04:18PM  
Aug-04-21 08:30AM  
Jul-21-21 08:30AM  
Jul-12-21 08:30AM  
Jul-07-21 08:30AM  
Jun-22-21 08:00AM  
Jun-02-21 08:30AM  
May-06-21 07:00AM  
May-04-21 08:00AM  
Apr-20-21 02:02AM  
Apr-13-21 08:30AM  
Apr-12-21 08:30AM  
Mar-19-21 10:00AM  
Mar-11-21 07:10AM  
Mar-09-21 08:30AM  
Mar-02-21 08:30AM  
Feb-17-21 08:30AM  
Feb-16-21 08:30AM  
Feb-12-21 10:56AM  
Feb-08-21 08:30AM  
Feb-02-21 08:30AM  
Jan-29-21 04:05PM  
Jan-14-21 08:30AM  
Jan-05-21 08:30AM  
Dec-09-20 08:30AM  
Dec-08-20 08:30AM  
Dec-02-20 08:30AM  
Nov-23-20 08:30AM  
Nov-16-20 08:30AM  
Nov-11-20 08:30AM  
Nov-04-20 08:00AM  
Nov-02-20 05:48AM  
Oct-21-20 08:30AM  
Oct-14-20 04:05PM  
Oct-09-20 08:30AM  
Sep-29-20 08:00AM  
Sep-11-20 09:00AM  
Sep-10-20 09:15AM  
Aug-31-20 06:12PM  
Aug-26-20 09:30AM  
Aug-05-20 11:04AM  
Jul-14-20 09:25AM  
Jun-29-20 08:30AM  
Jun-03-20 09:30AM  
09:00AM  
May-12-20 09:30AM  
May-06-20 09:09AM  
Apr-14-20 08:30AM  
Mar-23-20 09:00AM  
Mar-02-20 09:07AM  
Feb-24-20 09:00AM  
Feb-03-20 11:42AM  
08:30AM  
Jan-29-20 09:00AM  
Jan-14-20 08:00AM  
Dec-09-19 08:30AM  
Nov-25-19 08:00AM  
Nov-18-19 08:30AM  
Nov-14-19 09:00AM  
Oct-29-19 08:30AM  
Oct-22-19 09:00AM  
Sep-18-19 08:00AM  
Sep-11-19 09:00AM  
Sep-04-19 01:34PM  
Jul-15-19 04:01PM  
Jul-10-19 07:23AM  
Jun-25-19 01:00PM  
May-08-19 04:05PM  
Jan-03-19 07:00AM  
Oct-09-18 08:00AM  
Jul-03-18 08:00AM  
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1 clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences has research collaboration with Trinity College Dublin to Investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was founded in 2011 and is headquartered in La Jolla, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gorgas Gregory D.Pres, CEO, CFO, Treas & SecrApr 16Buy1.158,5009,809270,676Apr 20 04:10 PM